RECENT NEWS /EVENTS

RECENT NEWS /EVENTS

EPO supports new platform on renewable energy innovation

Published in RECENT NEWS /EVENTS Written by Published in RECENT NEWS /EVENTS 0 comment

10 July 2015

Policy makers and other energy sector players now have consolidated access to the world's largest collection of global renewable energy standards and patent documents, thanks to a new online platform launched by the International Renewable Energy Agency (IRENA) in co-operation with the EPO. Also known as INSPIRE, the International Standards and Patents in Renewable Energy platform is the first and most complete solution of its kind, helping users locate, search and analyse more than two million patent documents and 400 international standards relating to renewable energy and carbon mitigation technologies.

"The INSPIRE platform demonstrates the role of the patent system in supporting innovation in renewable energy, encouraging research and development in technologies to serve modern energy needs while addressing climate change," said EPO President Benoît Battistelli. "INSPIRE also showcases the role of patent information, which provides up-to-date information on technologies and their inventors to advise policy makers on the renewable energy sector."

The result of collaboration between IRENA, the EPO and the International Electrotechnical Commission (IEC), INSPIRE has multiple functionalities:

§  The patents section contains information on over two million patent documents relating to carbon mitigation technologies from the world's most comprehensive global patent statistics database, PATSTAT, and links to the world's most comprehensive public online search tool for patent documents, Espacenet, including its dedicated "Y02" patent classification scheme for carbon mitigation technologies.

§  The standards section enables users to search through a database of more than 400 internationally used standards and generate reports as needed. It also explains what standards are, how they can be used and why they are important for quality assurance, investor confidence and technology trading.

The combination of resources on INSPIRE will help users analyse various aspects of renewable energy policy and innovation. It can help indicate the effectiveness of policies to promote renewable energy innovation through the analysis of trends in patent activity. Users can also perform metadata analysis of technology trends, comparing development within, or between, different technologies. For example, the number of patents filed for renewable energy technology has increased annually by more than 20 per cent in recent years, while the average increase for other technologies is around 6 per cent.

"The INSPIRE platform provides insight on where renewable energy technology is developing the quickest, and which countries and companies are active in which technologies," said IRENA Director-General Adnan Z. Amin. "It helps bring together vast collections of renewable energy patent documents and standards, which can foster collaboration between innovators, spur improvement through product comparison and benchmarking and help identify partners, matching domestic energy needs to innovative energy solutions."

"By linking the technical information in IEC International Standards to practical applications in renewable energy, INSPIRE will be a precious resource for energy regulators," said IEC General Secretary & CEO Frans Vreeswijk. "It will assist policy makers in finding relevant international standards faster and more efficiently. It will also help educate stakeholders about the strategic role of international standards and conformity assessment for the cost-efficient expansion of renewable energy generation." 

Source: http://www.epo.org/news-issues/news/2015/20150710.html

Read more...

IPAB sets aside Patent Office's order in an appeal of HUL

Published in RECENT NEWS /EVENTS Written by Published in RECENT NEWS /EVENTS 0 comment

The case relates to a water purification system that is being opposed by Eureka Forbes

T E Narasimhan & Gireesh Babu | Chennai

July 7, 2015 Last Updated at 20:48 IST

The Intellectual Property Appellate Board (IPAB) has set aside an order of the Patent Office, which revoked a patent granted to Hindustan Unilever Ltd related to a water purification system following an opposition raised by Eureka Forbes Limited.

The appeal was filed by HUL against an order of the Assistant Controller of Patents and Designs dated March 14, 2012, revoking the patent number 198316 granted to its application titled "a gravity fed water purification system". Eureka Forbes, a rival firm, had filed an opposition against the patent.

S Majumdar, counsel appeared for Hindustan Unilever contended that while the Assistant Controller of Patents and Designs has received the recommendations of Board of Examination, he has not furnished those recommendations or objections either to Hindustan Unilever Ltd or to Eureka Forbes. He argued that thus, the company has been prevented from replying to the objections or giving explanations and the order under challenge was passed mechanically violating the principles of natural justice.

The counsel for the opposite party, while commenting that the patent official referred about the receipt of the recommendations of the Board of examination and even the Member of the Board was also present, farily admitted that the recommendations or objections raised by the Opposition Board were not furnished to either of the parties.

After hearing all the sides, IPAB's bench comprising Chairman Justice K N Basha and Technical Member (Patent) DPS Parmar, stated that the "undisputed fact remains that the Assitant Controller of Patents & Designs has received the recommendations and objections of the Board of Examination and unfortunatley the said recommendations and objections were furnished neither to the appellant (HUL) nor to the respondent (Eureka Forbes)".

Observing that it is incumbent on the part of the Controller to constitute an Oppoition Board as per provisions under the Patents Act, 1970 and provide an opportunity for being heard to the patentee and as well as to the opponent on receipt of the recommendation of the Opposition Board.

The IPAB also observed that the provisions makes it crystal clear that the Controller has not only authorise to constiute an Opposition Board but also duty bound to offer opportunity of being heard to the patentee and to the appellant on receipt of the recommendation of the Opposition Board.

"We have no hesitation to hold that the impugned order was passed in flagrant violation of the principles of natural justice," said the IPAB order.

The Bench, observing that the order of the Assistant Controller of Patents and Designs was passed in violation of principles of natural justice, has set-aside the order and directed the Controller to consider the matter afresh by affording opportunity to both sides by furnishing copies of Opposition Board Report and affording further opportunity to give their explanation and reply and their submissions and pass order on merits in accordance with law.

"It is made very clear that the above said exercise shall be completed within a period of six months from the date of receipt of the order copy of this Bench," according to the Order passed by Justice K N Basha, chairman and D P S Parmar, technical member (patents).

 

Source: http://www.business-standard.com/article/companies/ipab-sets-aside-patent-office-s-order-in-an-appeal-of-hul-115070701247_1.html

Read more...

TAKE Solutions secures patent for clinical data standardization process

Published in RECENT NEWS /EVENTS Written by Published in RECENT NEWS /EVENTS 0 comment

The author has posted comments on this articleSindhu Hariharan, TNN | Jun 25, 2015, 03.28PM IST

CHENNAI: TAKE Solutions -- a Chennai-based global business technology solutions provider -- has been awarded a patent by the United States Patent and Trademark Office ( USPTO) for its clinical data standardization process.

The process, delivered by Navitas -- the life sciences arm of TAKE Solutions -- is referred to as "Method for Optimizing Clinical Data Standardization."

This process captures data from clinical trials coming in different formats and leverages TAKE's clinical accelerator systems to standardize the data.

According to TAKE, the patented process is capable of reducing the time taken to standardize trial data, thus simplifying the analysis process by regulators and also reducing time to market.

"The process includes various pre-defined steps that convert raw data into tabular data sets. This enables regulators to easily understand the data, as well as enables easy analysis of trial data," TAKE Solutions said in a statement.

"The clinical data and regulatory service accounts for almost 30% of our life sciences business and we expect the patented process to reduce cost of providing the services by around 20%," Srinivasan H R, vice-chairman and MD of TAKE Solutions, told TOI.

TAKE's clinical data and regulatory services team offers clinical data solutions, including clinical data standardisation, clinical data management, statistical programming and data standards.

 

Source: http://timesofindia.indiatimes.com/business/india-business/TAKE-Solutions-secures-patent-for-clinical-data-standardization-process/articleshow/47814558.cms?

Read more...

India, Japan to sign pact on increasing IP cooperation

Published in RECENT NEWS /EVENTS Written by Published in RECENT NEWS /EVENTS 0 comment

The Memorandum of Cooperation will be signed between the Department of Industrial Policy and Promotion and the Japan Patent Office

Press Trust of India  |  New Delhi 

June 25, 2015 Last Updated at 00:38 IST

The government today approved the signing of an agreement with Japan to increase cooperation in the field of industrial property (IP).

The decision regarding this was taken by the Union Cabinet chaired by Prime Minister Narendra Modi.

The Memorandum of Cooperation will be signed between the Department of Industrial Policy and Promotion (DIPP) and the Japan Patent Office (JPO).

"The purpose of MoC is to establish a framework for bilateral cooperation in the field of IP, with emphasis on capacity building, human resource development and awareness generation," an official statement said.

The pact also aims at increasing efforts to support innovation in both the countries.

To be renewed automatically every four years, the MoC will be implemented through biennial Action Plans. The first plan is ready for implementation.

Areas on which both the sides will work include information sharing on IP protection systems and practices; and cooperation in the area of examination, including utilisation of the examiner-exchange programme.

They will also enhance cooperation in the scheme of the Patent Cooperation Treaty; assistance in developing IP infrastructure; capacity building in the use of IT infrastructure; and awareness building for the general public.

The key feature of the pact will be building awareness among the general public about the most important property rights for the 21st century.

To this end, the JPO will impart training at its own cost to individuals, people in educational institutions, lawyers, corporate employees and judges, besides examiners and other IPO officials.

The exchange of best practices between the two countries is expected to improve protection and awareness about India's range of intellectual creations which are as diverse as its people, including patents, trademarks, designs and geographical indications.

 

Source: http://www.business-standard.com/article/pti-stories/india-japan-to-sign-pact-on-increasing-ip-cooperation-115062400733_1.html

Read more...

Bengaluru-based IT firms lead patent hunt

Published in RECENT NEWS /EVENTS Written by Published in RECENT NEWS /EVENTS 0 comment

Karnataka has surged ahead in the number of patents filed in 2013-14 with Bengaluru-based Samsung R&D Institute (84); Infosys (83); Wipro Ltd (59); Samsung India Software Operations Pvt. Ltd. (66) top filers from among infotech companies.

Indian Space Research Organisation (12), Indian Institute of Science (32) and Siddaganga Institute of Technology, Tumakuru, (24) figure in the top 10 scientific bodies and institutions.

The city’s lush landscape of research entities continues to be a main draw for new R&D players and expansions of older companies.

A recent report by IBEF lists Chinese company Huawei’s plan to invest $170 million in an R&D campus in the city.

It also mentions similar plans from China’s smart phone manufacturer Xiaomi and Twitter to have an R&D presence in the city.

Kalyan C. Kankanala, Managing Partner of IP consultant BananaIP, told The Hindu that a National IP Policy was in the pipeline as well as a State IP policy. The policy would confirm the two governments’ stands on incentives and tax benefits and influence the next moves of industry and institutions, even as general awareness about patenting was increasing.

 

Source: http://www.thehindu.com/news/cities/bangalore/bengalurubased-it-firms-lead-patent-hunt/article7339968.ece

Read more...

Cipla, BMS settles patent dispute

Published in RECENT NEWS /EVENTS Written by Published in RECENT NEWS /EVENTS 0 comment

Parties seek confidentiality of the terms of settlement

BS Reporter | Chennai

June 17, 2015 Last Updated at 18:00 IST

The patent dispute between US-based pharma major Bristol-Myers Squibb (BMS) and Indian pharma major Cipla Ltd over entecavir, a pharmaceutical combination for treating Hepatitis B has been settled amicably out of the court. Based on the endorsement made in this regard by both the parties, the Intellectual Property Appellate Board (IPAB) today dismissed theoriginal rectification application filed by Cipla against BMS's patent.

Counsels appearing for both the parties informed the Appellate Board that the matter has been settled out of court in April, 2015. Taking the endorsement to the registry on record, the bench comprising of IPAB Chairman Justice K N Basha and Technical Member (Patent) DPS Parmar dismissed the application as withdrawn not pressed. The companies requested the terms of settlement has to be kept confidential.

Cipla, in 2010, has filed a revocation application with the IPAB to revoke the patent, for a pharmaceutical composition comprising up to one per cent of entecavir effective for once a day oral administration to treat Hepatitis B virus infection in a human adult patient. It may be noted that another Indian generic firm Natco Pharma Ltd has earlier settled the dispute on the same product amicably.

Source: http://www.business-standard.com/article/companies/cipla-bms-settles-patent-dispute-115061700840_1.html

Read more...

Snapdeal faces Heat for Misusing Nalli's Trademark, Photos

Published in RECENT NEWS /EVENTS Written by Published in RECENT NEWS /EVENTS 0 comment

By Express News Service

CHENNAI: Iconic saree retailer Nalli Chinnasami Chetty has initiated legal action against leading e-commerce giant Snapdeal.com for ‘dishonestly’ using their trademark and brand on the site.

A statement from Nalli here on Wednesday said that they had issued a Cease & Desist Notice to Snapdeal.com on June 11 in using trademark and photographs of their product in any manner.

This was a clear case of copyright and trademark infringement, said a Nalli spokesperson.

According to him, not only was Snapdeal using the Nalli trademark as a search word an act of property infringement, the sarees on display were also claimed to be Nalli silk sarees.

“That is completely untrue and leads buyers to think they originated from Nalli,” he said.

Nalli’s statement also listed all such links and how it had noticed the infringement. “Nalli Chinnasami Chetty are the registered owners of the trademark “Nalli” in Class 24, 25 and various other goods falling within  the ambit of classes 14, 9 and services under classes 35,36,37 41 & 42.  “On Friday, June 11, 2015 we noticed while undertaking a Google search for “nalli.com” that Snapdeal had misused our registered trademark “Nalli”, as well as copied the photographic images from Nalli’s website,” it said. The weblinks which misused the brand name, included in the statement, led to Snapdeal’s clothing segment, said Nalli.

“More specifically, it leads to the online sale of silk sarees where Nalli products and images from our website nalli.com have been dishonestly used.

It is a deliberate attempt by Snapdeal to deceive the public to unjustly enrich itself to make the public assume that the original “Nalli” silk sarees are available on their website,” said the statement, adding that the online sale of Nalli products are done exclusively through their website “nalli.com” and nowhere else. “Hence, we have demanded that Snapdeal immediately cease & desist using their trademark Nalli as search criteria or in any other manner and to remove all photographic images of their products from Snapdeal’s website,” said a Nalli spokesperson.

 A Snapdeal spokesperson, however, said that while they were taking appropriate action, “Snapdeal.com is an online marketplace which connects buyers and sellers to provide the widest assortment of products. We have received the notice from the company and will take appropriate actions as per law.”

Source: http://www.newindianexpress.com/cities/chennai/Snapdeal-faces-Heat-for-Misusing-Nallis-Trademark-Photos/2015/06/18/article2872611.ece

Read more...

Nokia, LG join hands; inks smartphone patent license

Published in RECENT NEWS /EVENTS Written by Published in RECENT NEWS /EVENTS 0 comment

By: PTI | June 16, 2015 5:17 pm

LG Electronics will soon embed technologies developed by Nokia in its smartphones as the Korean firm has agreed to take a royalty-bearing smartphone patent license from the Finnish telecom gear maker.

“We are pleased to welcome LG Electronics to our licensing program,” Nokia Technologies President Ramzi Haidamus said in a statement.

LG Electronics is the latest of more than 60 licensees for Nokia’s 2G, 3G and 4G mobile communication technologies and the first major smartphone manufacturer to join the licensing program since Nokia divested its Devices and Services business to Microsoft in 2014.

“We’ve worked constructively with LG Electronics and agreed on a mutually beneficial approach, including the use of independent arbitration to resolve any differences. This agreement sets the scene for further collaboration between our companies in future,” Haidamus said.

The detailed royalty payment obligations will be subject to commercial arbitration and is expected to conclude within a 1-2 year timeframe. Other terms of the agreement remain confidential.

First Published on June 16, 2015 4:38 pm

Source: http://www.financialexpress.com/article/industry/companies/nokia-lg-join-hands-inks-smartphone-patent-license/85752/

Read more...

Opto Circuits subsidiary wins patent case against US firm to get Rs 147 crore towards loss of royalty from Zoll LifeCor

Published in RECENT NEWS /EVENTS Written by Published in RECENT NEWS /EVENTS 0 comment

BS Reporter  |  Bengaluru 

June 9, 2015 Last Updated at 00:48 IST

Opto Circuits (India), maker of invasive and non-invasive medical equipment and devices, has won a patent violation case against US-based Zoll LifeCor Corporation. According to a Los Angeles Superior Court verdict delivered late last month, the US firm will pay $23 million (Rs 147 crore) towards the loss of royalty to Opto Circuits group company Cardiac Science Corporation.

Cardiac Science, which makes automated external defibrillators (AEDs), was represented by law firm Patterson Thuente Pedersen.

A defibrillator is a piece of equipment used to control the movements of the heart muscles by giving the heart a controlled electric shock.

The dispute relates to the company's patented wearable defibrillator technology. In 2002, LifeCor began marketing its LifeVest product, which violated a number of patents of Cardiac Science. To avoid patent-violation claims, LifeCor entered into a cross-licence pact with Cardiac Science and was able to sell its device. In 2006, Zoll Medical Equipment acquired LifeCor. It stopped paying royalties linked to the agreement. Cardiac Science sued Zoll Medical and Zoll Lifecor for violation of contract in 2011.

“This unanimous jury verdict represents a significant victory for Cardiac Science and the extensive damages validate the significant value of Cardiac Science’s wearable defibrillator technology and other technologies in the AED space,” said Vinod Ramnani, chairman and managing director of Opto Circuits (India).

Cardiac Science develops, manufactures and markets automated external defibrillators. The company has customers in 100 countries and has operations in North America, Europe and Asia.

Source:http://www.business-standard.com/article/companies/opto-circuits-owned-firm-to-get-23-million-in-royalty-115060800556_1.html

Read more...

India to resist Japan and South Korea's push for patent legislation at RCEP

Published in RECENT NEWS /EVENTS Written by Published in RECENT NEWS /EVENTS 0 comment

By Dilasha Seth, ET Bureau | 12 Jun, 2015, 04.38AM IST

NEW DELHI: India will resist a push by Japan and South Korea for stringent patent legislation at the eighth round of negotiations for Regional Comprehensive Economic Partnership (RCEP), according to a senior official.

Ten ASEAN countries and their freetrade agreement partners--Australia, China, India, Japan, Korea and New Zealand--are currently holding the eight round of talks in Kyoto and hope to create an Asian free-trade block—RCEP— by the year end. The negotiations seeks to include goods, services, investments, competition and intellectual property.

New Delhi has maintained that its intellectual property rights regime is WTO compliant and will not talk beyond its global commitments made under Trade-Related Aspects of Intellectual Property Rights (TRIPS). India, instead, is pushing for protection of traditional knowledge. As per the draft text submissions, Japan and South Korea have proposed provisions beyond the WTO, such as patent term extensions, data exclusivi and lowering of the patentability criteria.

The current round of negotiations will conclude on June 13. The negotiations saw protests from public health activists and the civil society, cautioning about the adverse impact of such IP provisions on accessibility of low-cost medicines in developing countries.

"If accepted, these provisions would extend monopoly protection beyond what is required," said Loon Gangte of a civil society group-DNP+ and International Treatment Preparedness Coalition- South Asia. Japan and Korea have the backing of Australia, New Zealand, Malaysia and Singapore and other fellow countries in the Trans Pacific Partnership (TPP), which is another proposed regional free trade agreement under which these countries are negotiating with the US. Korea has, in its draft text, said that the patent term must be adjusted to compensate for unreasonable delays in granting the patent. "An unreasonable delay shall at least include a delay in the issuance of the patent of more than four years from the date of filing of the application...," it has proposed. "We are clear about our red lines in the negotiation and we are not going to talk beyond TRIPS," the Indian official said.

Japan, on the other hand, is pushing for patents to be granted for incremental innovations, even when they don't show any improved efficacy over an existing invention. Section 3(d) of India's patent law forbids patenting of incremental innovations called 'evergreening'. This clause was also upheld by the SC in 2013 when it turned down Swiss drug innovator Novartis' plea for patenting its cancer drug Glivec.

 

Source: http://economictimes.indiatimes.com/news/economy/policy/india-to-resist-japan-and-south-koreas-push-for-patent-legislation-at-rcep/articleshow/47636517.cms

Read more...